Journal: Cell Reports Medicine

Article Title: In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF V600E lung adenocarcinoma

doi: 10.1016/j.xcrm.2024.101663

Figure Lengend Snippet:

Article Snippet: Fluvastatin sodium , TargetMol , Cat#T1487.

Techniques: Recombinant, Glutathione Assay, Flow Cytometry, shRNA, Control, Plasmid Preparation, Software

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 1 Effect of treatment on xenograft tumour volumes and weights. (A) Picture of a CMT cell line xenograft mouse with a tumour in the inguinal fat pad on day 28 of treatment (star). (B) Graph showing the difference in tumour volumes between Day 0 and day 28 of treatment for the four groups (n = 16-control, 14-fluvastatin, 8-doxorubicin and 8-combined fluvastatin and doxorubicin). The combination therapy group shows a significant difference in tumour volumes from the control. (C) Graph showing final tumour weights on day 28. There is a significant difference in tumour weights between the control group and the doxorubicin treatment group but not between the control group and the other groups. Data are presented as means (columns) ± SEM (error bars). Asterisks (*) indicate a statistically significant difference (*P < .05) between groups.

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 2 Effect of fluvastatin on tumour ischemic necrosis. (A) Graph showing the percentage of tumour necrosis in all four groups. (B) Tumours from control mice and from mice treated with fluvastatin were evaluated for ischemic necrosis (black stars) (n = 16 controls and 14 fluvastatin). (C) Picture of the annotated area of necrosis (white stars) according to Qupath. Data are presented in the graph as means (columns) ± SEM (error bars).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 3 Effect of fluvastatin treatment on tumour cell apoptosis and tumour cell proliferation. (A, B, D, E) Photomicrographs of Ki-67 immunohistochemistry at 200 and 1000 for control group (A and D) and Fluvastatin treated group (B and E). (C) Graph showing the percentage of positive tumour cells for Ki-67 for both groups (n = 7-control and 6-fluvastatin). (G—J) Photomicrographs of cleaved caspase 3 immunohistochemistry at 200 and 1000 for control group (G and I) and Fluvastatin treated group (H and J). (F) Graph showing the percentage of positive tumour cells for cleaved caspase 3 for both groups (n = 7-control and 6-fluvastatin). Data in both graphs are presented as means (columns) ± SEM (error bars).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Immunohistochemistry, Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 5 Cytoplasmic and nuclear Allred scores for YAP Immunohistochemistry signal. (A, B, D, E) Photomicrographs of immunohistochemistry for YAP at 200 and 1000 in control group (A and D), and in the fluvastatin treated group (B and E). (C) Nuclear and (F) cytoplasmic graphs of Allred score for YAP in control and fluvastatin treated group (n = 7 control and n = 6-fluvastatin). Data are presented in the graph as means (columns) ± SEM (error bars).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Immunohistochemistry, Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 4 Effect of treatment on tumour dissemination. (A) Graph showing the number of xenograft lung metastases in the control group (n = 9) and in the fluvastatin treated group (n = 7). (B and C) photomicrographs of lung without metastasis (B) and with two xenograft metastases (higher magnification in inlay) (C).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 7 Effect of fluvastatin on four Hippo pathway's target genes. mRNA levels of (A) CTGF (B) ANKRD1, (C) RHAMM2 and (D) CYR61 were determined by RT-qPCR and data normalised to the housekeeping gene RPL19 (n = 15-control and 12-fluvastatin). Data are presented as means (columns) ± SEM (error bars).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Quantitative RT-PCR, Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 6 Cytoplasmic and nuclear Allred scores for TAZ Immunohistochemistry signal. (A, B, D, E) Photomicrographs of immunohistochemistry for YAP at 200 and 1000 in control group (A and D), and in the fluvastatin treated group (B and E). (C) Nuclear and (F) cytoplasmic graphs of Allred score for YAP in control and fluvastatin treated group (n = 7 control and n = 6-fluvastatin). Data are presented in the graph as means (columns) ± SEM (error bars).

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Immunohistochemistry, Control

Journal: Veterinary and comparative oncology

Article Title: Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.

doi: 10.1111/vco.12926

Figure Lengend Snippet: FIGURE 8 Detection of fluvastatin in tumour tissues (ng/g) in murine xenografts treated with vehicle or fluvastatin. Mice received IP injection of vehicle (10% DMSO in PBS) or fluvastatin (30 mg/kg) three times a week for 4 weeks (28 days). (A) Example of reconstructed ion chromatograms for fluvastatin. Chromatogram overlays are presented for two extracted control and two treated samples. (B) Graph showing concentration of fluvastatin between 144 and 1018 ng/g in Fluvastatin treated group (n = 16 controls and n = 14 fluvastatin). (C) Descriptive statistics for each group.

Article Snippet: Fluvastatin (100 mg) was purchased at Toronto Research chemicals # F601250 and doxorubicin (5 mg) was purchased at Cayman Chemicals # 15007.

Techniques: Injection, Control, Concentration Assay